Of these, BCAS3, COL4A1, COL4A2, SMAD3 and CYP17A1 had evidence of estrogen modulating some aspect of CAD development, and the rest had estrogen modulation evidence in other tissues (e.g., breast tissue, uterine endothelium). This evidence concerns the gene SMAD3 and coronary artery disorder.